Nuo Therapeutics, Inc. (AURX): debt financing — Nuo Therapeutics secures up to $1.6M loan with 10%-12% PIK interest paid in warrants; insider participation

Nuo Therapeutics, Inc.

Loan agreement for $1.0M initial + $600K second tranche (Sept 30, 2026); $1.0M funded Jan 23, 2026.
Interest 10% annual on initial note, rising to 12% if second tranche is taken; accrued interest paid only in warrants at maturity.
Principal repaid in 8 equal quarterly installments from Mar 31, 2027 to Dec 31, 2028; early prepayment fee 1.5-2.75% of principal paid in warrants.
Lenders include director/10% owner Scott Pittman ($200K) and >5% owner Paul Jacobs ($300K); each received initial and potential second warrants.
Warrants exercisable at $1.50/share, expiring Jan 23, 2031; up to 226,000 interest warrant shares issuable at maximum borrowing.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Nuo Therapeutics, Inc. incurred credit facility of aggregate principal amount of up to $1.6 million with four lenders (including Scott M. Pittman and Paul Anthony Jacobs) at annual rate of 10% maturing December 31, 2028.

Instrument: credit facility
Principal: aggregate principal amount of up to $1.6 million
Counterparty: four lenders (including Scott M. Pittman and Paul Anthony Jacobs)
Rate: annual rate of 10%
Maturity: December 31, 2028
Event: incurrence

Exact text from the filing

On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million with (a) $1.0 million funded on the initial closing date (the “Initial Funding”) and (b) $600 thousand to be funded, if requested in advance by the Company and subject to closing conditions, on September 30, 2026 (the “Second Funding”).

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Nuo Therapeutics, Inc. issued warrant to four lenders (collectively, the 'Lenders').

Security: warrant
Purchaser: four lenders (collectively, the 'Lenders')

Exact text from the filing

On January 23, 2026, the closing date of the Initial Funding, and pursuant to the Loan Agreement, the Company issued to each Lender warrants, some of which are subject to vesting provisions, to purchase shares of the Company’s common stock

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Nuo Therapeutics, Inc. entered into Loan and Security Agreement with four lenders (collectively, the "Lenders") valued at up to $1.6 million (effective 2026-01-21).

Action: entry
Agreement: credit facility
Counterparty: four lenders (collectively, the "Lenders")
Value: up to $1.6 million
Effective: 2026-01-21

Exact text from the filing

On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million

View on SEC.gov

26 debt financings filed in the last 30 days. Browse all debt financings →

Nuo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-002078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.